$0.06
(Market cap
$90 Mln
Revenue (TTM)
$31 Mln
P/E Ratio
142
P/B Ratio
2.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
26.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.1
-
Face value
--
-
Shares outstanding
9,082,197
10 Years Aggregate
CFO
$-0.03 Mln
EBITDA
$2.16 Mln
Net Profit
$-11.60 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ImmuCell (ICCC)
| 60.1 | -12.2 | -3.9 | 53.8 | 28.8 | 1.5 | 3.3 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ImmuCell (ICCC)
| 19.4 | 1.2 | -16.6 | -23.8 | 34.5 | 15.5 | -26.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ImmuCell (ICCC)
|
9.8 | 90.3 | 30.7 | 0.8 | 3.8 | 2.7 | 142 | 2.9 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.7 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 361.2 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 539.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 584.5 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 351.0 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout ImmuCell (ICCC)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and... Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine. Read more
-
President, CEO, Principal Financial Officer, Treasurer, Secretary & Director
Mr. Michael F. Brigham
-
President, CEO, Principal Financial Officer, Treasurer, Secretary & Director
Mr. Michael F. Brigham
-
Headquarters
Portland, ME
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ImmuCell (ICCC)
What is the current share price of ImmuCell Corporation (ICCC) Today?
The share price of ImmuCell Corporation (ICCC) is $9.85 (NASDAQ) as of 01-Sep-2026 14:03 EDT. ImmuCell Corporation (ICCC) has given a return of 28.78% in the last 3 years.
What is the current PB & PE ratio of ImmuCell Corporation (ICCC)?
The P/E ratio of ImmuCell Corporation (ICCC) is 142.00 times as on 28-Aug-2026.
The P/B ratio of ImmuCell Corporation (ICCC) is 2.91 times as on 28-Aug-2026, a 44 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-53.49 |
2.06 |
2024 |
-21.34 |
1.67 |
2023 |
-6.83 |
1.58 |
2022 |
-18.95 |
1.56 |
2021 |
-782.57 |
1.88 |
What is the 52 Week High and Low of ImmuCell Corporation (ICCC)?
The 52-week high and low of ImmuCell Corporation (ICCC) are Rs 12.10 and Rs 4.52 as of 02-Sep-2026.
What is the market cap of ImmuCell Corporation (ICCC)?
ImmuCell Corporation (ICCC) has a market capitalisation of $ 90 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in ImmuCell Corporation (ICCC)?
Before investing in ImmuCell Corporation (ICCC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.